Abstract |
Forty-six women with breast cancer treated with adjuvant FAC ( fluorouracil, doxorubicin and cyclophosphamide) entered a multicenter, randomized, double-blind, cross-over trial in which thiethylperazine (T) (6.5 mg p.o every 8 h x 3 days) plus methylprednisolone (MP) (250 mg i.v. x 2 doses) was compared with thiethylperazine plus placebo. Forty-four patients were evaluable for efficacy. T + MP was significantly better in reducing vomiting (p less than 0.01) and nausea (p less than 0.02). The complete protection rate against vomiting was 36% for T + MP compared to 18% for T + placebo, and the percentage of nausea grades 0 + 1 (none or slight) was 59% and 27% respectively. The patient preference after cross-over was strikingly in favor of T + MP (70% versus 13%) (p less than 0.001). The most important side-effects of T + MP were facial flushing (22%) and euphoria (27%). Other side-effects, such as dryness of the mouth and sedation, were common after both treatments. In conclusion, the study suggested that T + MP is superior to T alone in protecting from nausea and vomiting induced by FAC.
|
Authors | E Diaz-Rubio, M Martin, R Rosell, J J Valerdi, J L Gonzalez-Larriba, J J Barriga |
Journal | Acta oncologica (Stockholm, Sweden)
(Acta Oncol)
Vol. 30
Issue 3
Pg. 339-42
( 1991)
ISSN: 0284-186X [Print] England |
PMID | 2036244
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiemetics
- Doxorubicin
- Thiethylperazine
- Cyclophosphamide
- Fluorouracil
- Methylprednisolone
|
Topics |
- Antiemetics
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy)
- Cyclophosphamide
(administration & dosage)
- Double-Blind Method
- Doxorubicin
(administration & dosage)
- Drug Therapy, Combination
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Methylprednisolone
(adverse effects, pharmacology, therapeutic use)
- Middle Aged
- Thiethylperazine
(adverse effects, therapeutic use)
|